Research & KnowledgeEvent: September 1, 2026
eptivA Therapeutics Ltd. published a study showing that GLP-1 receptor agonists increase the risk of developing diabetic lumbosacral radiculoplexus neuropathy
Published
Signal category
Research & Knowledge
Quote
“another study found GLP-1RA users were more likely to develop diabetic lumbosacral radiculoplexus neuropathy”
— Mark J. Field|eptivA Therapeutics Ltd. team
Company
eptivA Therapeutics Ltd.
A clinical stage biotech company utilising novel Personalized Analgesics® research to create precision pain medicines
- Industry
- Biotechnology Research
- Location
- Oxford, GB
- Company size
- 2 employees
Eptiva Therapeutics is a clinical stage Biotech company transforming the way pain is treated with PERSONALIZED ANALGESICS®. We have invented novel in silico research methods to create the first precision medicine approach to pain.